Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Aromatase inhibitors have been approved for use in postmenopausal women to treat and prevent
breast cancer. They act by blocking the action of the enzyme, aromatase, that is necessary
for the production of estradiol. This class of drugs, aromatase inhibitors, are very
effective in reducing estradiol levels in postmenopausal women and in treating estrogen
receptor positive breast cancers. This study is examining the effect of a specific inhibitor,
anastrozole, on endometrial thickness in premenopausal women. The endometrium is sensitive to
estradiol and also has local aromatase which, if inhibited, may result in reduced endometrial
thickness. The main hypothesis is that anastrozole can be administered at any time during the
menstrual cycle and reduce endometrial thickness compared to placebo.